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TO THE EDITOR
Microparticles (MPs) are membrane
vesicles of 0.1 to 1 mm diameter gener-
ated by budding or shedding from the
plasma membrane and released by any
cell type into the vascular compartment
during activation or apoptosis (The´ry
et al., 2009). Membrane lineage mar-
kers of their originating cell permit
to distinguish several circulating MPs,
such as platelet-derived MPs (PMPs) or
endothelial cell-derived MPs (EMPs).
Microparticles are involved in inflam-
matory and auto-immune diseases, as
well as in cardiovascular disorders and
the metabolic syndrome (Helal et al.,
2010; Leroyer et al., 2010). MP impli-
cation in psoriasis pathophysiology is
suggested by several features: (i) the
pathogenic role of TNF-a (Nestle et al.,
2009), a powerful in vitro inducer of
EMP generation (Combes et al., 1999);
(ii) the presence of activated endothe-
lial cells within cutaneous lesions
(Nestle et al., 2009) and EMP genera-
tion that may reflect endothelium
aggression; and (iii) the presence
of platelet activation in psoriasis
(Garbaraviciene et al., 2010; Tamagawa-
Mineoka et al., 2010) that may generate
PMPs (Italiano et al., 2010). Moreover,
the association between psoriasis and
atherosclerotic risk factors (Boehncke
et al., 2010) may be related to excessive
MP production. Based on this, we
investigated circulating MPs in psoriatic
patients.
The study design was approved by
the local research ethics committee and
written informed consent was provided
before enrolment. The study adhered to
the Declaration of Helsinki Principles.
Fifty-two psoriatic patients analyzed
before the introduction of systemic
treatments and 30 healthy blood donors
were investigated (Table 1). Patients
with other dermatosis, with a history
of cardiovascular disease, diabetes,
chronic renal failure, or chronic inflam-
matory disease, were excluded. The
severity of psoriasis was evaluated by
the Psoriasis Area Severity Index (PASI)
and the Dermatology Life Quality
Index (DLQI) scores. We adapted the
MP quantification method developed
by Robert et al. (2009). Plasma was
separated from whole blood by centri-
fugation at 1500 g for 15minutes.
Recovered plasma was centrifuged for
2min at 13,000 g to remove residual
cells and platelets. Microparticles were
labeled using FITC-conjugated Annex-
in-V (AV) (BD Biosciences, Le Pont de
Claix, France) and fluorescent mAbs
were added to identify the MP cellular
origin. The following mAbs were used:
phycoerythrin (PE)-conjugated CD31
and PE-Texas Red-x (ECD)-conjugated
CD41 (Beckman Coulter, Villepinte,
France), PE-conjugated CD62E (BD
Biosciences), and fluorescent-conjugated
isotype control mAbs. After 30-minute
incubation and addition of Flow-SetTM
fluorosphere beads (Beckmann Coulter),
samples were analyzed using a NAVIOS
cytometer (Beckman Coulter). MP
number was calculated on the basis of
the known number of Flow-SetTM beads
added to the sample. EMPs were identi-
fied as CD31þ /CD41/AVþ / or
CD62Eþ /CD41/AVþ / events, and
PMPs as CD31þ /CD41þ /AVþ / events
(Figure 1a–e, Supplementary Table S1
online). Two MP-size regions were
determined and standardized daily with
Megamix fluorescent beads (Biocytex,
Marseille, France) containing two types
of beads with a defined size (0.5 and
0.9mm diameter, respectively). Two
nonparametric statistical tests (Wilcoxon
and Kruskal–Wallis tests) were used to
compare the means of circulating MP
counts.
Circulating EMP levels were incre-
ased in psoriatic patients (Table 1,
Figure 1f and g). Circulating CD31þ
41 EMPs were statistically higher
compared with EMP levels in the
control group (80 ml1, ±121 vs.
12 ml1, ±10; P¼0.0002). A trend
toward significance was observed for
CD62Eþ EMPs (5 ml1, ±5 in patients
vs. 3 ml1, ±2 in healthy subjects;
P¼0.09). When focusing on the smal-
ler-size EMPs, we found a significantly
higher number of both CD31þ /CD41
EMPs (54 ml1, ±82 vs. 8 ml1, ±7;
Po0.0001) and CD62Eþ EMPs (4 ml1,
±4 vs. 2 ml1, ±2; P¼ 0.006) in
psoriatic patients. When considering
larger-size EMPs (X0.5 mm), we de-
tected a significantly higher number of
CD31þ /CD41 EMPs (30 ml1,±52) in
patients than in the control group
(3 ml1,±4; P¼0.0035). No significant
difference was observed for CD62Eþ
EMPs. No correlation with psoriasis
severity (assessed by PASI and DLQI
scores) was observed. No difference
was found in circulating CD31þ /
CD41þ PMP levels between psoriatic
patients (5,621ml1, ±7,030) and
healthy controls (4,515ml1, ±3,787;
P¼0.35). However, smaller-size PMP
levels were significantly higher in psor-
iatic patients than in healthy patients
(3,528ml1, ±5,122 vs. 1,508ml1,
Abbreviations: AV, Annexin-V; DLQI, Dermatology Life Quality Index; EMP, endothelial-derived
microparticle; MP, microparticle; PASI, Psoriasis Area Severity Index; PMP, platelet-derived
microparticle; TNF-a, tumor necrosis factor-alpha
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±964, P¼ 0.007). We did not observe
any correlation with psoriasis severity.
Total circulating AVþMP counts
(whatever their origin) in psoriatic
patients (3,052 ml1, ±2,852) did not
significantly differ from those quantified
in the control group (3,177ml1,
±2,568, P¼0.83). There was no
difference depending on the size of
AVþMPs (Table 1).
Our study demonstrates that circu-
lating EMPs and small-size PMPs
are significantly increased in psoriatic
patients as compared with healthy
subjects. Tamagawa-Mineoka et al.
(2010) previously showed that plasma
PMP levels were significantly increased
in 21 psoriasis patients. The discre-
pancy with our results may be related
to the methods used for PMP quanti-
fication: ELISA versus flow cytometry.
Cytometry permits to determine MP
size (Orozco and Lewis, 2010). Small-
size PMPs –identified here– may reflect
platelet activation. Several evidences
suggest that the majority of PMPs
circulating in healthy subjects are
derived from megakaryocytes, while
PMPs derived from activated platelets
have been separated into four size
classes, including small-size PMPs
(Italiano et al., 2010), with different
functional effects on platelets and
endothelial cells (Dean et al., 2009).
Soluble P-selectin level, a platelet-
activation hallmark, is a biomarker for
inflammation in psoriasis (Garbaravi-
ciene et al., 2010). Increased EMP
levels could be explained by endothe-
lial cell activation by TNF-a, since
TNF-a favors in vitro EMP generation
(Combes et al., 1999). We showed that
EMPs induce plasmacytoid dendritic
cell (pDC) maturation (Angelot et al.,
2009). As pDCs are essential to drive
psoriasis development (Nestle et al.,
2005), EMPs could represent an activat-
ing factor for pDCs and thus contribute
to inflammation. Systemic inflammation
in turn causes insulin resistance in
psoriasis, a state in which insulin is
proatherogenic (Boehncke et al., 2007).
As both small-size PMPs (Dean et al.,
2009) and EMPs (Leroyer et al., 2010)
express procoagulant phosphatidylserine
and tissue factor activities, increased
small-size PMP and EMP levels may
Table 1. Main clinical characteristics of subjects and plasma levels of EMPs, PMPs, and AV+ MPs in patients with
psoriasis and in healthy control subjects
Control, n=30 Psoriasis, n=52 P
Age (years)a 50 (18–65) 51.8 (25–96) NS
Sex (male/female) 15/15 29/23 NS
C-reactive protein (mg l1)a 1.0 (1–1) 5.46 (1–11) ND
PASI scorea ND 18 (14–25) ND
DLQIa ND 12.5 (0–26) ND
EMPsb
Total CD31+/CD41 EMPs 12±10 (2–44)b 80±121 (3–543) 0.0002
0.5–0.9 mm CD31+/CD41+ EMPs 3±4 (0–15) 26±52 (0–222) 0.0035
o0.5 mm CD31+/CD41 EMPs 8±7 (0–29) 54±82 (0–433) o0.0001
Total CD62E+/CD41 EMPs 3±2 (0–12) 5±5 (0–24) 0.09
0.5–0.9 mm CD62E+/CD41 EMPs 1±1 (0–6) 2±3 (0–16) 0.21
o0.5 mm CD62E+/CD41 EMPs 2±2 (0–5) 4±4 (0–13) 0.006
PMPsb (CD31+/CD41+) 4,515±3,787 (829–16279)b 5,621±7,030 (340–31,054) 0.35
0.5–0.9 mm PMPs 3,006±2,921 (230–11332) 2,092±2,331 (86–10,049) 0.12
o0.5 mm PMPs 1,508±964 (321–4947) 3,528±5,122 (254–22,291) 0.007
AV+ MPsb 3,052±2,850 (422–10568)b 3,177±2,568 (129–11,537) 0.83
0.5–0.9 mm AV+ MPs 2,020±1,807 (153–6435) 1,428±1,391 (43–7,280) 0.10
o0.5 mm AV+ MPs 1,157±860 (240–4144) 1,623±1,631 (87–6,667) 0.09
Abbreviations: AV, Annexin-V; DLQI, Dermatology Life Quality Index; EMPs, endothelial-derived microparticles; MPs, microparticles; ND, not determined;
NS, nonsignificant; PASI, Psoriasis Area Severity Index; PMPs, platelet-derived microparticles.
aResults are expressed as median (range).
bResults are expressed as the mean number±standard deviation of microparticles per plasma ml (range). Microparticle size (that is, between 0.5 and 0.9 mm
or o0.5 mm) is also considered.
Bold values are statistically significant.
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contribute to accelerated atherosclerosis
in psoriatic patients. However, the clin-
ical relevance of our results remains still
disputed: does EMP generation represent
an epiphenomenon related to endothe-
lium activation by TNF-a or do EMPs
have a role in psoriasis pathophysiology
–through pDC activation– leading to
accelerated atherosclerosis?
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Figure 1. Analysis of circulating microparticles using a NAVIOS cytometer. (a) Standardized microparticle (MP) detection areas (0.5–0.9 and o0.5 mm) are
represented in the side scatter/forward scatter dot plot. Platelet-derived microparticles (PMPs; 31þ 41þ ) are depicted in green, the endothelial-derived
microparticles (EMPs; 31þ41 or 62Eþ41) in red. All histograms represent the analysis of a sample from the same psoriatic patient. (b, c) Analysis of 31þ41þ ,
41þ /62Eþ , or IgGþ /41þ events in the MP size areao0.5 mm: 31þ41 EMPs, PMPs, and 62Eþ41 EMPs are quantified in b.1, b.2, and c.1 areas, respectively.
(c.2, b.3–4): IgG isotypic control. (d, e) Analysis in the 0.5–0.9-mm size area. (f) The small-size EMP and PMP levels in psoriatic patients compared with healthy
subjects (HCs). (g) Idem for EMPs and PMPs quantified in the 0.5–0.9-mm size region.
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TO THE EDITOR
Transient receptor potential vanilloid
type 1 (TRPV1) is a non-selective cation
channel widely expressed in skin tis-
sues, including keratinocytes and per-
ipheral sensory nerve fibers (C and Ad).
Activated by noxious heat, capsaicin, or
endogenous inflammatory mediators,
TRPV1 can provoke neuropeptide re-
leases and propagate neurogenic inflam-
mation, which ultimately contributes
to the development of diverse derma-
toses and pruritus (Hutter et al., 2005;
Shim et al., 2007; Imamachi et al.,
2009). Recently, we demonstrated that
a novel and potent TRPV1 antagonist,
PAC-14028 ((E)-N-((R)-1-(3,5-difluoro-
4-methanesulfonylamino-phenyl)-ethyl)-
3-(2-propyl-6-trifluoromethyl-pyridine-
3-yl)-acrylamide) can alleviate atopic
dermatitis (AD)-like symptoms through
the acceleration of skin barrier re-
covery (Yun et al., 2011). Of note,
we discovered that PAC-14028 could
also suppress scratching behavior sig-
nificantly. Severe itch symptom is a
hallmark of AD and at the same time,
the representative unmet medical need
in diverse skin diseases (Steinhoff et al.,
2006). Here, we investigated the anti-
pruritic effects of PAC-14028 and ex-
plored the mechanism underlying them
to examine the utility of a TRPV1 anta-
gonist as a novel antipruritic therapy.
AD-like symptoms were induced in
male NC/Nga mice (8-week old, twice
a week for 3 weeks) with the repeated
topical application of allergen, Derma-
tophagoides farina (Df) extract, the
major species of house dust mites, on
the shaved dorsum as previously de-
scribed (Bae et al., 2010). All animal
experiment procedures were approved
by the AmorePacific Institutional Ani-
mal Care and Use Committee. PAC-
14028, which is a potent and selec-
tive TRPV1 antagonist as determined
by resiniferatoxin-induced Ca2þ influx
assay in rat TRPV1-expressed CHO
cells (Figure 1a) and capsaicin-induced
Ca2þ influx in dorsal root ganglia
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